Document Detail


Effects of acute administration of acylated and unacylated ghrelin on glucose and insulin concentrations in morbidly obese subjects without overt diabetes.
MedLine Citation:
PMID:  19628651     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To investigate the effects of unacylated ghrelin (UAG) and co-administration of acylated ghrelin (AG) and UAG in morbid obesity, a condition characterized by insulin resistance and low GH levels. DESIGN AND METHOD: Eight morbidly obese non-diabetic subjects were treated with either UAG 200 microg, UAG 100 microg in combination with AG 100 microg (Comb) or placebo in three episodes of 4 consecutive days in a double-blind randomized crossover design. Study medication was administered as daily single i.v. bolus injections at 0900 h after an overnight fast. At 1000 h, a standardized meal was served. Glucose, insulin, GH, free fatty acids (FFA) and ghrelin were measured up to 4 h after administration. RESULTS: Insulin concentrations significantly decreased after acute administration of Comb only, reaching a minimum at 20 min: 58.2 + or - 3.9% of baseline versus 88.7 + or - 7.2 and 92.7 + or - 2.6% after administration of placebo and UAG respectively (P<0.01). After 1 h, insulin concentration had returned to baseline. Glucose concentrations did not change after Comb. However, UAG administration alone did not change glucose, insulin, FFA or GH levels. CONCLUSION: Co-administration of AG and UAG as a single i.v. bolus injection causes a significant decrease in insulin concentration in non-diabetic subjects suffering from morbid obesity. Since glucose concentration did not change in the first hour after Comb administration, our data suggest a strong improvement in insulin sensitivity. These findings warrant studies in which UAG with or without AG is administered for a longer period of time. Administration of a single bolus injection of UAG did not influence glucose and insulin metabolism.
Authors:
Rosalie M Kiewiet; Maarten O van Aken; Kim van der Weerd; Piet Uitterlinden; Axel P N Themmen; Leo J Hofland; Yolanda B de Rijke; Patric J D Delhanty; Ezio Ghigo; Thierry Abribat; Aart Jan van der Lely
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial     Date:  2009-07-23
Journal Detail:
Title:  European journal of endocrinology / European Federation of Endocrine Societies     Volume:  161     ISSN:  1479-683X     ISO Abbreviation:  Eur. J. Endocrinol.     Publication Date:  2009 Oct 
Date Detail:
Created Date:  2009-09-21     Completed Date:  2009-10-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9423848     Medline TA:  Eur J Endocrinol     Country:  England    
Other Details:
Languages:  eng     Pagination:  567-73     Citation Subset:  IM    
Affiliation:
Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Turin, Molinette Hospital, Corso Dogliotti 14, 10126, Turin, Italy. r.kiewiet@erasmusmc.nl
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acylation
Adult
Blood Glucose / metabolism*
Cross-Over Studies
Diabetes Mellitus / blood*
Double-Blind Method
Drug Combinations
Fasting / physiology
Fatty Acids, Nonesterified / blood
Female
Ghrelin / adverse effects,  analogs & derivatives*,  pharmacology*
Humans
Insulin / blood*
Middle Aged
Obesity, Morbid / blood*
Tachyphylaxis / physiology
Chemical
Reg. No./Substance:
0/Blood Glucose; 0/Drug Combinations; 0/Fatty Acids, Nonesterified; 0/Ghrelin; 11061-68-0/Insulin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Association of hypovitaminosis D with metabolic disturbances in polycystic ovary syndrome.
Next Document:  Calcium-dependent and Calcium-independent inhibition of contraction by cGMP/cGKI in intestinal smoot...